MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.

Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS, MESEMS study group.

Open source

DOI: 10.1186/s13063-019-3346-z
Published: 2019-05-09
Container: Trials
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13063-019-3346-z,
  title = {MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.},
  author = {Uccelli A and  Laroni A and  Brundin L and  Clanet M and  Fernandez O and  Nabavi SM and  Muraro PA and  Oliveri RS and  Radue EW and  Sellner J and  Soelberg Sorensen P and  Sormani MP and  Wuerfel JT and  Battaglia MA and  Freedman MS and  MESEMS study group.},
  year = {2019},
  journal = {Trials},
  doi = {10.1186/s13063-019-3346-z},
  url = {https://doi.org/10.1186/s13063-019-3346-z}
}

RIS

TY  - JOUR
TI  - MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.
AU  - Uccelli A
AU  -  Laroni A
AU  -  Brundin L
AU  -  Clanet M
AU  -  Fernandez O
AU  -  Nabavi SM
AU  -  Muraro PA
AU  -  Oliveri RS
AU  -  Radue EW
AU  -  Sellner J
AU  -  Soelberg Sorensen P
AU  -  Sormani MP
AU  -  Wuerfel JT
AU  -  Battaglia MA
AU  -  Freedman MS
AU  -  MESEMS study group.
PY  - 2019
JO  - Trials
DO  - 10.1186/s13063-019-3346-z
UR  - https://doi.org/10.1186/s13063-019-3346-z
ER  -

APA

A, U., A, L., L, B., M, C., O, F., SM, N., PA, M., RS, O., EW, R., J, S., P, S. S., MP, S., JT, W., MA, B., MS, F., & group., M. S. (2019). MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.. Trials. https://doi.org/10.1186/s13063-019-3346-z

Source records

europe-pmc · retrieved 2026-09-26T15:58:10.490Z
doaj · retrieved 2026-09-26T15:58:10.500Z